Mankind Pharma

Quick check

The five things to look at first. Open one for more.

• DebtHigh safetyRated AA+ by 2 agencies.
• ResultsGrowingIn the Jun 2026 quarter, sales rose 13% and profit rose 29% from a year earlier.
• DilutionNo new sharesNo new shares issued in the last year, so existing shareholders' slices were not cut.
• PromotersSteadyThe promoters (founders or parent) own 73% of the company, about the same as in Jun 2025.
• ValuationCheap vs its pastThe share trades at 44.1 times its yearly earnings (P/E), cheaper than 95% of the time in the last 3 years. Its usual P/E is about 50.

Mankind Pharma against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

• Valuation (P/E)44.1 against a typical 34.3: pricier than most peers (1st = cheapest).142nd of 220
• Sales growth+12.9% against a typical +15.6% from a year earlier.109th of 197
• Profit growth+29% against a typical +18.9% from a year earlier.71st of 160
• Share price, 3 months−4% against a typical −0.5%.116th of 200
• Size₹ 91,572.1 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).7th of 199

Exchange filings and their impact on the company.

• 26 Oct 2026Outcome of Board MeetingHigh impactVery positivePrice +4.5% that day
  Strong Q2 with 17% revenue and 38% profit growth plus debt reduction supports higher earnings and net worth over next year.

  Mankind Pharma reported Q2 FY27 consolidated revenue of Rs 4,337.86 crore, up 17.3% year-on-year, and net profit of Rs 716.12 crore, up 37.7%, with H1 revenue of Rs 8,368.45 crore. Finance costs fell sharply and net debt declined to Rs 2,706.78 crore with all NCD covenants met. The board also approved merging two wholly-owned subsidiaries into itself and noted merger of Upakarma Ayurveda into Mankind Consumer Products, with no share issuance, alongside a favourable tax appeal deleting Rs 369.44 crore of additions.

  Full analysisFiling
• 15 Oct 2026Outcome of Board MeetingLow impactPositivePrice −3.1% on 16 Oct
  Mankind to invest ~Rs 430cr for 70% of CAR-T biotech ACTx, a small strategic bet with no near-term sales.

  Mankind Pharma's board on October 15, 2026 approved investing up to EUR 45 million in its Dutch subsidiary, taking the total limit to EUR 50 million, to acquire a 70% stake in Belgium-based Armed Cell Therapeutics for EUR 48 million in instalments. Armed Cell Therapeutics is developing next-generation CAR-T cancer therapies with lead programs in non-Hodgkin lymphoma and small cell lung cancer. The deal marks Mankind's strategic entry into innovative cell therapy with no sales contribution expected in the next 12 months.

  Full analysisFiling

Results dates and other board meetings. Full calendar

Compounded yearly rates over each period.

Listed companies in the same business.

Ramesh Juneja

Executive Chairman of the Board

Sheetal Arora

Chief Executive Officer, Whole-Time Director

Rajeev Juneja

Executive Vice Chairman of the Board, Managing Director

Ashutosh Dhawan

Global Chief Financial Officer

Prakash Agarwal

President - Strategy

Atish Majumdar

Senior President - Sales and Marketing

Birendra Singh

Senior President - Global Quality Head

Abhay Kumar Srivastava

Senior President - Operations